Smith & Nephew (NYSE:SNN; LSE:SN), the global medical
technology business, welcomes the launch of new medical
technologies guidance from the UK National Institute for Health and
Care Excellence (NICE). In the guidance, NICE recommends that PICO
Single Use Negative Pressure Wound Therapy System (sNPWT) should be
considered as an option for closed surgical incisions in patients
who are at high risk of surgical site infections (SSIs).1 Key
patient risk factors include a high BMI, diabetes, renal
insufficiency and smoking.2
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190509005087/en/
New NICE guidance recognises that Smith
& Nephew’s PICO™ sNPWT provides better outcomes than standard
dressings in patients at high risk of surgical site infections, at
similar overall cost (Photo: Business Wire)
NICE concluded that PICO sNPWT is associated with fewer SSIs and
seromas compared with standard wound dressings across several types
of surgery. Cost modelling suggests that compared with standard
wound dressings, PICO sNPWT provides extra clinical benefits at
similar overall cost to the NHS.1 For some types of surgery, PICO
sNPWT is cost saving.1
When making its recommendations, NICE considered a review of 31
studies, 15 of which were randomised controlled trials. 1 A
supporting meta-analysis showed that PICO reduced the risk of SSIs
by 63%, the risk of seroma by 77% and the risk of dehiscence by
30%.3 Significantly, it also showed there was an almost 2-day
reduction in length of hospital stay, providing substantial cost
savings and efficiency gains across the healthcare system.3
“Surgical site complications are an increasing concern for
healthcare providers and patients,” said Simon Fraser, President,
Advanced Wound Management, Smith & Nephew. “NICE’s recognition
of the proven impact PICO can make on both clinical outcomes and
cost efficiencies will hopefully challenge existing standards of
care around the world.“
The PICO sNPWT dressing includes a proprietary AIRLOCK™
Technology layer that uniformly and consistently delivers
sufficient NPWT across a surgical incision and the surrounding zone
of injury.4,5 This unique feature is designed to help reduce the
risk of wound complications by reducing post-operative fluid6,7 and
tension*8 around a closed surgical incision, when compared with
standard dressings. The combination of these actions helps reduce
the risk of surgical wound dehiscence3 and SSIs3, the two most
common surgical site complications.
To learn more about the NICE recommendations and PICO sNPWT
please visit http://www.smith-nephew.com/piconiceguidance/
- ends -
* as demonstrated in biomechanical modelling
References
1. NICE Medical Technology Guidance MTG43. PICO Negative
Pressure Wound Dressings for closed surgical incisions. May 9th
2019
2. World Union of Wound Healing Societies (WUWHS) Consensus
Document. Closed surgical incision management: understanding the
role of NPWT. Wounds International, 2016
3. Smith & Nephew. April 2019. Outcomes following PICO
compared to conventional dressings when used prophylactically on
closed surgical incisions: systematic literature review and
meta-analysis. Report reference EO/AWM/PICO/004/v3
4. Smith & Nephew October 2017. Project Opal PICO 7 System
Stability Testing, Initial Time Point. Internal Report.
DS/17/253/R.
5. Malmsj� M, Huddleston, E., and Martin, R., .Biological
Effects of a Disposable, Canisterless Negative Pressure Wound
Therapy System. ePlasty. 2014;14.
6. Karlakki SL, Hamad AK, Whittall C, et al.Incisional negative
pressure wound therapy dressings (iNPWTd) in routine primary hip
and knee arthroplasties: A randomised controlled trial. Bone Joint
Res. 2016;5(8):328-337.
7. Payne C, Edwards D.Application of the Single Use Negative
Pressure Wound Therapy Device ( PICO ) on a Heterogeneous Group of
Surgical and Traumatic Wounds. ePlasty. 2014:152-166.
8. Loveluck J, Copeland, T., Hill, J., Hunt, A., and Martin, R.,
.Biomechanical Modeling of the Forces Applied to Closed Incisions
During Single-Use Negative Pressure Wound Therapy. ePlasty.
2016.
NICE has checked the use of its content in this product. NICE
is independent of any company or product advertised.
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business
with leadership positions in Orthopaedics, Advanced Wound
Management and Sports Medicine. Smith & Nephew has more than
16,000 employees and a presence in more than 100 countries. Annual
sales in 2018 were $4.9 billion. Smith & Nephew is a member of
the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith
& Nephew, please visit our corporate
website www.smith-nephew.com and follow us
on Twitter, LinkedIn or Facebook.
To learn more about how we can help you get CLOSER TO ZERO™
surgical site complications, please visit www.closertozero.com
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190509005087/en/
EnquiriesMediaRachel CunninghamROAD
CommunicationsRachel@roadcommunications.co.uk+44-(0)20-8995-5832Dave
SnyderSmith & Nephew+1-(978)-749-1440
Smith & Nephew (LSE:SN.)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Smith & Nephew (LSE:SN.)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024